<DOC>
	<DOC>NCT00230490</DOC>
	<brief_summary>Compare the long-term safety of pradefovir to adefovir dipivoxyl</brief_summary>
	<brief_title>Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201</brief_title>
	<detailed_description>- Compare the long-term safety of pradefovir to adefovir dipivoxyl - Monitor development of resistance - Evaluate virologic and biochemical response</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Patients who completed 48 weeks of treatment in study RNA200103201 Patients who were determined to be treatment failures in study RNA200103201 Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103201 Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103201</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Hepatitis B, Chronic</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Pradefovir Mesylate</keyword>
	<keyword>Adefovir Dipivoxyl</keyword>
</DOC>